Nimesulida Gp – Genéricos Portugueses (Nimesulide)

Nimesulide selectively blocks cyclooxygenase‑2 (COX‑2) enzymes, decreasing the synthesis of prostaglandins that mediate inflammation, pain, and fever. By limiting prostaglandin formation at the site of injury or systemic inflammation, the drug provides analgesic, anti‑inflammatory, and antipyretic effects.

The appropriate dose of Nimesulida Gp is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of nimesulide in pregnancy and lactation has not been established. It is generally avoided during the first trimester and throughout pregnancy unless the potential benefit outweighs the risk. Breastfeeding mothers should consult their physician, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimesulide is a COX‑2 preferential NSAID, offering analgesic and anti‑inflammatory benefits similar to ibuprofen or diclofenac but with a potentially lower risk of gastric irritation. However, it carries a distinct risk of hepatotoxicity, which requires periodic liver function monitoring, unlike some alternative NSAIDs.

Nimesulida Gp should be stored at room temperature, below 25 °C, in its original blister or bottle. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Nimesulida Gp is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include severe liver injury, potentially leading to hepatitis or liver failure, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Renal impairment and serious gastrointestinal bleeding are also important concerns that require prompt medical attention if symptoms arise.

Nimesulida Gp is contraindicated in patients with known hypersensitivity to nimesulide or other NSAIDs, active peptic ulcer disease, severe hepatic or renal impairment, and in individuals who have experienced serious skin reactions to NSAIDs. It should also be avoided in patients on certain anticoagulants or those with uncontrolled hypertension.